Pharmaceutical Industry Information Portal


All posts by tag


Bayer intends to discontinue partnership with Atara on CAR-T for $670 million

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and...

Bayer invests more than €1.3 billion in Leaps by Bayer to focus on Cell & Gene Therapy

Today, Bayer held its first ever Breakthrough Innovation Forum, focusing on longer-term opportunities for health and agriculture leveraging emerging technologies. In conjunction with the...

Pfizer, Bayer keep supplying drugs to Russia

Pfizer Inc and Bayer said on Monday they would maintain humanitarian supply of medicines to Russia, but would pull back from other non-essential spending...

Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics

Following closing of the acquisition, Bayer will own full rights to Vividion’s proprietary discovery platform, which comprises three integrated, synergistic components.

FAS fined Bayer for improper advertising

The FAS Russia imposed an administrative fine of 200 thousand rubles on Bayer JSC for improper advertising of the medicine Teraflex Hondrokrem Forte.

Bayer builds a new pharmaceutical facility in Finland

Bayer is building a new pharmaceutical facility in Turku and at the same time modernizing its existing production plant. The new production facility will...

Expert Articles